NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky, LLP announces that it has commenced an investigation of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ:SPPI) concerning possible violations of federal securities laws by the Company.

On September 14, 2016, an advisory committee to the U.S. Food and Drug Administration (“FDA”) unanimously voted against approval of Spectrum’s bladder cancer treatment, Qapzola™. Following this news, shares of Spectrum fell $0.45 per share from its previous closing price to close at $5.04 per share on September 14, 2016.

Then on September 16, 2016, an article published by TheStreet revealed that in a December 2012 meeting with the FDA, Spectrum was advised not to file a New Drug Application for Qapzola. Despite this advice, Spectrum told investors in a May 2015 conference call that “we took this data, met with the FDA, and our understanding is and our decision is that we can go ahead and file the NDA with this drug.”

To obtain additional information about the investigation, go to:

http://zlk.9nl.com/spectrumsppi

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160920006821/en/